COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
20/08/2025
Data to highlight the impact of Wegovy ® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus ® and Ozempic ® data demonstrate [...]
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
20/08/2025
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
InfoAging Launches Florida’s First Comprehensive “Care Team Finder” to Tackle Senior Health Crisis
20/08/2025
Miami, Florida, Aug. 20, 2025 (GLOBE NEWSWIRE) -- InfoAging , a specialized health directory for senior-focused care, today announced the launch of InfoAging.org , Florida’s first comprehensive “Care Team Finder” [...]
Sai Life Sciences secures SBTi validation for near-term climate targets
20/08/2025
HYDERABAD, India, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO) , announced that [...]
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
20/08/2025
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling [...]
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
20/08/2025
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
20/08/2025
Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion study [...]
Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy
20/08/2025
New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway WHITE PLAINS, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer in bio-interventional ophthalmic [...]
First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS
20/08/2025
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has [...]
L'hôpital universitaire de Heidelberg élargit son programme de thérapie par particules avec une solution Proteus®ONE
20/08/2025
Louvain-la-Neuve, Belgique, le 20 août 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution
20/08/2025
Louvain-La-Neuve, Belgium, August 20, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
20/08/2025
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 [...]
337,000 Orion Corporation A shares converted into B shares
20/08/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at 9.00 EEST 337,000 Orion Corporation A shares converted into B shares In accordance with [...]
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
20/08/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a [...]
Dallas Premier No Surgery Hair Replacement Folicure Hair Helps Men Reclaim Their Confidence in New Guide to Recognizing When Hair Loss Calls for Action
20/08/2025
Discover Best Dallas Premier No Surgery Hair Replacement guide to identifying hair loss and exploring tailored hair replacement solutions to regain confidence and restore your hairline. Dallas, TX, Aug. 19, 2025 (GLOBE [...]
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
19/08/2025
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage [...]
NMDP Announces Nationwide Celebration and Fundraiser to Help Patients in Need of Life-Saving Cell Therapy
19/08/2025
NMDP Unite will be held simultaneously on Sept. 20—World Marrow Donor Day—in Atlanta, Houston, New York, Minneapolis and Seattle MINNEAPOLIS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NMDP℠ (formerly Be The Match ® ), a global [...]
Arcutis to Present at Upcoming Investor Conferences
19/08/2025
WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Ligand to Participate in September Investor Conferences
19/08/2025
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in [...]

Pages